Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
PRINCETON, N.J. - CytoSorbents Corporation (NASDAQ: CTSO), a company specializing in blood purification technologies currently trading at $0.86 per share, announced significant findings from a real-world data analysis presented at the EuroPCR 2025 conference. According to InvestingPro analysis, while the company maintains strong liquidity with a current ratio of 2.61, it faces profitability challenges with negative earnings in the last twelve months. The study showed that the use of the CytoSorb® device during urgent coronary artery bypass grafting (CABG) surgery significantly reduced severe bleeding complications in patients who had not completed the recommended washout period for the blood thinner ticagrelor.
The analysis compared 150 patients from the STAR Registry who underwent surgery with the CytoSorb® device to 644 patients from a control group who did not use the device. Results indicated a significant decrease in severe bleeding according to the BARC-4 criteria (10.7% vs. 33% in the control group, p
Professor Robert F. Storey, who presented the findings, noted the device’s effectiveness in mitigating excess bleeding in patients undergoing CABG surgery without completing the ticagrelor washout period. Dr. Efthymios Deliargyris, Chief Medical Officer of CytoSorbents, emphasized the significance of these findings, suggesting that the device could become a standard part of care to reduce bleeding complications in patients on ticagrelor.
CytoSorbents’ technology is designed to remove toxic substances from blood using porous polymer beads. The CytoSorb® device, approved in the European Union and available in over 70 countries, is used for various applications, including the removal of blood thinners during cardiothoracic surgery. Financial data from InvestingPro reveals the company generates $35.33 million in annual revenue with an impressive gross profit margin of 69.23%. Get access to 6 additional ProTips and comprehensive financial analysis through InvestingPro’s detailed research reports, available for over 1,400 US stocks including CTSO.
While the company awaits regulatory decisions for its DrugSorb-ATR system in the United States and Canada, the positive real-world data from the STAR Registry supports the clinical value of the CytoSorb® therapy. This information is based on a press release statement from CytoSorbents Corporation.
In other recent news, CytoSorbents Corporation announced its first-quarter 2025 financial results, which fell short of market expectations. The company reported an earnings per share (EPS) of -$0.06, missing the forecast of -$0.05, and revenue of $8.7 million, significantly below the anticipated $10.82 million. Despite these results, CytoSorbents managed to reduce its operating loss by 17% year-over-year, with a gross margin remaining steady at 71%. The company is also focusing on strategic initiatives, such as establishing a new subsidiary in Dubai and appealing FDA decisions regarding its DrugSorb ATR device.
Moreover, CytoSorbents is preparing for a controlled market introduction of the DrugSorb ATR in the U.S. and Canada, pending regulatory approvals. Analysts from firms like Jefferies and H.C. Wainwright have shown interest in the company’s FDA appeal process and its implications for future growth. The company also highlighted its efforts to reignite growth in Germany, its largest market in the European Union, by reorganizing its sales strategy. CytoSorbents remains committed to reaching near breakeven by the end of 2025, with ongoing efforts to enhance operational efficiency and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.